Introducing Particle3D: revolutionizing the future of bone implants

PSV
2 min readAug 20, 2018

We are incredibly happy to welcome Particle3D as one of the newest family members in the PreSeed Ventures portfolio. Particle3D has through the last three years been developing a revolutionizing way to treat patients who need a bone transplant.

Patients needing bone replacement, often due to an accident or a disease, are today presented with options that often involve quite a few complications. The implants can be synthetic implants such as titanium, a donor bone or, a bone fragment harvested from the patient’s own bod. All of the solutions above can result in infection, inflammation or other complications.

Particle3D have developed a new way of 3D-printing bone implants that drastically reduces both risk and complications in bone transplantations. Particle 3D can potentially offer patients a better outcome after surgery, both functionally and aesthetically.

The bio-ink used in the 3D printer is based on calcium phosphate and fatty acids. This combination creates bone implants that over time becomes part of the body itself. It drastically limits the recovery time for patients and produces a much better outcome in the end.

Particle3D is a spinout from the University of Southern Denmark, where the scientific leader of jaw reconstruction, Torben Thygesen, asked for a new and less complicated way to treat his patients. That led to the two bachelor students, Casper Slots, and Martin Bonde Jensen, engaging in a project that eventually would become Particle3D. They showed their results to the 3D printing specialist Morten Østergaard, which laid the foundation for a future partnership as he’s today part of the founder team.

In 2015, the team filed for their first patent, and in 2017 things really started to look bright for the three 3D printing enthusiasts. They won VentureCup, a pitching competition for young startups and they were accepted into the incubator Accelerace.

The team is currently running tests with bone implants on pigs, which eventually should lead to testing on real-life human patients in 2019.

--

--

PSV
PSV

Written by PSV

PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter

No responses yet